Please login to the form below

Not currently logged in
Email:
Password:

Study clears Pfizer’s Champix of serious risks

Smoking-cessation drug 'does not increase risk' of depression or heart attacks
Pfizer building

New research indicates Pfizer's stop-smoking drug Champix may not increase the risk of depression and heart attacks as previously thought.

The study, published in The Lancet Respiratory Medicine, followed over 160,000 patients for five years who received nicotine replacement therapy (NRT), GlaxoSmithKline's anti-smoking drug Zyban (bupropion) or Pfizer's Champix (varenicline).

The researchers found that people taking either Champix or Zyban were no more likely to suffer a heart attack or develop depressive symptoms than those on NRT.

Additionally, use of Champix was associated with a significantly reduced risk of ischaemic heart disease, cerebral infarction, heart failure, arrhythmia and depression.

Aziz Sheikh, one of the study's researchers and co-director of the University of Edinburgh's Centre for Medical Informatics, said: “On the basis of our extensive analysis, we believe it is highly unlikely that varenicline has any significant adverse effects on cardiac or mental health.

“Regulators such as the Food and Drug Administration (FDA) should review their safety warning in relation to Champix as this may be unnecessarily limiting access to this effecting smoking cessation aid.”

The results come as good news for Pfizer, which is already undertaking a very similar study evaluating neuropsychiatric safety, the results for which will be available later this year.

Champix, marketed as Chantix in the US, achieved global sales of $647m in 2014 making it one of the highest-selling smoking cessation drugs.

However, since the controversy surrounding the drug's side effects, sales have fallen from 2007, when it brought in $883m.

Since 2008, the drug has been at the centre of nearly 3,000 lawsuits, however, all the cases were settled by Pfizer in June 2013.

Article by
Nikhil Patel

9th September 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical website. Support the...

Latest intelligence

Personalised medicine: driving a need for greater diversity in clinical trials
Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...